COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease.
Drug Discov Today
; 28(6): 103579, 2023 06.
Article
in English
| MEDLINE | ID: covidwho-2298216
ABSTRACT
The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the causative factor behind the 2019 global coronavirus pandemic (COVID-19). The main protease, known as Mpro, is encoded by the viral genome and is essential for viral replication. It has also been an effective target for drug development. In this review, we discuss the rationale for inhibitors that specifically target SARS-CoV-2 Mpro. Small molecules and peptidomimetic inhibitors are two types of inhibitor with various modes of action and we focus here on novel inhibitors that were only discovered during the COVID-19 pandemic highlighting their binding modes and structures.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Drug Discov Today
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2023
Document Type:
Article
Affiliation country:
J.drudis.2023.103579
Similar
MEDLINE
...
LILACS
LIS